Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5174967 | 0.99 | LMNA (0.43) | LMNANPC1RAB9AALDH1A1MAPT | |
| Ammonia Solution, Strong SCHEMBL8555602 | 0.94 | ALDH1A1 (0.48) | LMNANPC1RAB9AALDH1A1MAPT | |
| SCHEMBL4725543 | 0.92 | ALDH1A1 (0.49) | LMNANPC1RAB9AALDH1A1MAPT | |
| Sulfuric Acid SCHEMBL2532781 | 0.79 | TSHR (0.55) | LMNANPC1RAB9AALDH1A1MAPT | |
| Sulfuric Acid SCHEMBL6515066 | 0.79 | TSHR (0.55) | LMNANPC1RAB9AALDH1A1MAPT | |
| SCHEMBL9455051 | 0.72 | ALDH1A1 (0.42) | LMNANPC1RAB9AALDH1A1MAPT | |
| SCHEMBL23048563 | 0.72 | CNR1 (0.43) | LMNANPC1RAB9AALDH1A1MAPT | |
| SCHEMBL4623996 | 0.72 | ALDH1A1 (0.56) | LMNANPC1RAB9AALDH1A1MAPT | |
| SCHEMBL893600 | 0.72 | ALDH1A1 (0.56) | LMNANPC1RAB9AALDH1A1MAPT | |
| SCHEMBL29387616 | 0.72 | ALDH1A1 (0.56) | LMNANPC1RAB9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388244-B2 | Internalizing ErbB2 antibodies | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-07-12 | — | — | US | disclosed |
| US-9243057-B2 | Antibodies for botulinum neurotoxins | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-01-26 | — | — | US | disclosed |
| US-9181330-B2 | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150239976-A1 | Internalizing ErbB2 Antibodies | UNIV CALIFORNIA (US) | 2015-08-27 | — | — | US | disclosed |
| US-9000131-B2 | Antibodies that neutralize botulinum neurotoxins | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-04-07 | — | — | US | disclosed |
| US-8974792-B2 | Internalizing erbB2 antibodies | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-10 | — | — | US | disclosed |
| US-20150030600-A1 | Antibodies for Botulinum Neurotoxins | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-01-29 | — | — | US | disclosed |
| US-20140105910-A1 | Therapeutic Monoclonal Antibodies that Neutralize Botulinum Neurotoxins | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-04-17 | — | — | US | disclosed |
| US-20130337039-A1 | Internalizing ErBB2 Antibodies | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-12-19 | — | — | US | disclosed |
| US-8598321-B2 | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2313434-A2 | ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS | The Regent of the University of California (US) | 2011-04-27 | — | — | EP | disclosed |
| US-7892554-B2 | Using immunoglobulin fusion to deliver effector cells; tissue targeted therapy; antitumor agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100222555-A1 | Monoclonal antibodies that neutralize botulinum neurotoxin | THOMAS JEFFERSON UNIVERSITY (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100166773-A1 | THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-07-01 | — | — | US | disclosed |
| US-7700738-B2 | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090324606-A1 | THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-12-31 | — | — | US | disclosed |
| US-20090123481-A1 | THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-14 | — | — | US | disclosed |
| US-20080108135-A1 | Internalizing ErbB2 antibodies | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-05-08 | — | — | US | disclosed |
| US-20020155114-A1 | THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS | ARMY MEDICAL RESEARCH AND MATERIEL COMMAND, UNITED STATES GOVERNMENT SECRETARY OF THE | 2002-10-24 | — | — | US | disclosed |
| US-5652333-A | IMMUNOGENS, TREATMENT OF HIV | TANOX BIOSYSTEMS, INC. (US) | 1997-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222555-A1 | Monoclonal antibodies that neutralize botulinum neurotoxin | BTN3A1, ANTXR2, BTD | LMNA 1813/4885NPC1 3741/4885RAB9A 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.